Volume 13 Issue 7
Jul.  2015
Turn off MathJax
Article Contents
Abstract
References
Rachel A. Ness, Duane D. Miller, Wei LI. The role of vitamin D in cancer prevention[J]. Chinese Journal of Natural Medicines, 2015, 13(7): 481-497.
Citation: Rachel A. Ness, Duane D. Miller, Wei LI. The role of vitamin D in cancer prevention[J]. Chinese Journal of Natural Medicines, 2015, 13(7): 481-497.
shu

The role of vitamin D in cancer prevention

  • Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA

Funds: 

This work was supported by NIH grants 1R21AR063242 (W.L. and D.D.M.) and 1R01CA148706 (W.L.).

More Information
  • Received Date: 09-May.-2015
    Graphical Abstract
    • Abstract
  • Vitamin D, also known as cholecalciferol, is the precursor to the active steroid hormone 1, 25-dihydroxyvitamin D3 (calcitriol; 1, 25(OH)2D3). The main physiological role for 1, 25(OH)2D3 is to regulate calcium and inorganic phosphate homeostasis for bone health. More recently, vitamin D has been investigated for its effects in the prevention and treatment of a variety of diseases such as cancer, autoimmune disorders, and cardiovascular disease. Preclinical data strongly support a role for vitamin D in the prevention of cancer through its anti-proliferative, pro-apoptotic, and anti-angiogenic effects on cells. Epidemiologic and clinical studies have shown mixed data on the correlation between serum vitamin D levels and cancer risk. This report seeks to outline results from the most recent preclinical and clinical studies investigating the potential role of vitamin D in cancer prevention.
    • FullText(HTML)
    • References (139)
  • [1]
    Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer?[J]. Int J Epidemiol, 1980, 9(3):227-231.
    [1]
    Krishnan AV, Trump DL, Johnson CS, et al. The role of vitamin D in cancer prevention and treatment[J]. Endocrin Metab Clin, 2010, 39(2):401-418.
    [2]
    Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression[J]. Nat Rev Cancer, 2014, 14(5):342-357.
    [3]
    Feldman D, Pike JW, Adams JS. Vitamin D[M]. 3rd Ed Elsevier Academic Press, 2011.
    [4]
    Moukayed M, Grant WB. Molecular link between vitamin D and cancer prevention[J]. Nutrients, 2013, 5(10):3993-4021.
    [5]
    Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer:potential for anticancer therapeutics[J]. Nat Rev Cancer, 2007, 7(9):684-700.
    [6]
    Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D:an endocrine society scientific statement[J]. Endocr Rev, 2012, 33(3):456-492.
    [7]
    Pereira F, Larriba MJ, Muoz A. Vitamin D and colon cancer[J]. Endocr-Relat Cancer, 2012, 19(3):R51-R71.
    [8]
    Wranicz J, Szostak-Wegierek D. Health outcomes of vitamin D. Part II. Role in prevention of diseases[J]. Rocz Panstw Zakl Hig, 2014, 65(4):273-279.
    [9]
    Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine:What clinicians need to know[J]. J Clin Endocr Met, 2011, 96(1):53-58.
    [10]
    Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency:an endocrine society clinical practice guideline[J]. J Clin Endocr Met, 2011, 96(7):1911-1930.
    [11]
    Hobaus J, Thiem UM, Hummel D, et al. Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis[J]. Anti-Cancer Agent Me, 2013, 13(1):20-35.
    [12]
    Holick MF. Vitamin D and bone health[J]. J Nutr, 1996, 126(4 Suppl):1159S-1164S.
    [13]
    Fleet JC, DeSmet M, Johnson R, et al. Vitamin D and cancer:a review of molecular mechanisms[J]. Biochem J, 2012, 441(1):61-76.
    [14]
    Huhtakangas JA, Olivera CJ, Bishop JE, et al. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1,25(OH)2-Vitamin D3 in vivo and in vitro[J]. Mol Endocrinol, 2004, 18(11):2660-2671.
    [15]
    Nemere I, Farach-Carson MC, Rohe B, et al. Ribozyme knockdown functionally links a 1, 25(OH)2D3 membrane binding protein (1, 25D3-MARRS) and phosphate uptake in intestinal cells[J]. P Natl A Sci USA, 2004, 101(19):7392-7397.
    [16]
    Jensen SS, Madsen MW, Lukas J, et al. Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phasecontrolling machinery[J]. Mol Endocrinol, 2001, 15(8):1370-1380.
    [17]
    Salehi-Tabar R, Nguyen-Yamamoto L, Tavera-Mendoza LE, et al. Vitamin D receptor as a master regulator of the c-MYC/MXD1 network[J]. P Natl A Sci USA, 2012, 109(46):18827-18832.
    [18]
    Meyer MB, Goetsch PD, Pike JW. VDR/RXR and TCF4/betacatenin cistromes in colonic cells of colorectal tumor origin:impact on c-FOS and c-MYC gene expression[J]. Mol Endocrinol, 2012, 26(1):37-51.
    [19]
    Washington MN, Kim JS, Weigel NL. 1alpha, 25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest[J]. Prostate, 2011, 71(1):98-110.
    [20]
    Li P, Li C, Zhao X, et al. P27(Kip1) stabilization and G(1) arrest by 1, 25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclindependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase[J]. J Biol Chem, 2004, 279(24):25260-25267.
    [21]
    Akutsu N, Lin R, Bastien Y, et al. Regulation of gene expression by 1alpha, 25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells[J]. Mol Endocrinol, 2001, 15(7):1127-1139.
    [22]
    Bao BY, Hu YC, Ting HJ, et al. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells[J]. Oncogene, 2004, 23(19):3350-3360.
    [23]
    Chiang KC, Yeh CN, Chen SC, et al. MART-10, a new generation of vitamin D analog, Is more potent than 1alpha, 25-Dihydroxyvitamin D(3) in inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells[J]. Evid-Based Compl Alt 2012, 2012:310872.
    [24]
    Diaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells:possible implications for prevention and therapy[J]. Cancer Res 2000, 60(8):2304-2312.
    [25]
    Liu CY, Flesken-Nikitin A, Li S, et al. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development[J]. Genes Dev, 1996, 10(14):1835-1843.
    [26]
    Pendas-Franco N, Aguilera O, Pereira F, et al. Vitamin D and Wnt/beta-catenin pathway in colon cancer:role and regulation of DICKKOPF genes[J]. Anticancer Res, 2008, 28(5A):2613-2623.
    [27]
    Gocek E, Studzinski GP. Vitamin D and differentiation in cancer[J]. Crit Rev Cl Lab Sc, 2009, 46(4):190-209.
    [28]
    Villaggio B, Soldano S, Cutolo M. 1, 25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages[J]. Clin Exp Rheumatol, 2012, 30(6):934-938.
    [29]
    Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells:a crosstalk interrupted by vitamin D3[J]. Oncogene, 2009, 28(44):3892-3902.
    [30]
    Kovalenko PL, Zhang Z, Cui M, et al. 1, 25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1[J]. BMC Genomics, 2010, 11:26.
    [31]
    Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis[J]. Carcinogenesis, 2006, 27(9):1883-1893.
    [32]
    Tse AK, Zhu GY, Wan CK, et al. 1alpha, 25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells[J]. Mol immunol, 2010, 47(9):1728-1738.
    [33]
    Dormoy V, Beraud C, Lindner V, et al. Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma[J]. Carcinogenesis, 2012, 33(11):2084-2093.
    [34]
    Krishnan AV, Shinghal R, Raghavachari N, et al. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays[J]. Prostate, 2004, 59(3):243-251.
    [35]
    Figueroa JA, De Raad S, Tadlock L, et al. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer[J]. J Urology, 1998, 159(4):1379-1383.
    [36]
    Kriebitzsch C, Verlinden L, Eelen G, et al. The impact of 1, 25(OH)2D3 and its structural analogs on gene expression in cancer cells--a microarray approach[J]. Anticancer Res, 2009, 29(9):3471-3483.
    [37]
    Lee HJ, Liu H, Goodman C, et al. Gene expression profiling changes induced by a novel gemini vitamin D derivative during the progression of breast cancer[J]. Biochem Pharmacol, 2006, 72(3):332-343.
    [38]
    Swami S, Raghavachari N, Muller UR, et al. Vitamin D growth inhibition of breast cancer cells:gene expression patterns assessed by cDNA microarray[J]. Breast Cancer Res Tr, 2003, 80(1):49-62.
    [39]
    Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling[J]. J Cell Biol, 2001, 154(2):369-387.
    [40]
    Beildeck ME, Islam M, Shah S, et al. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines[J]. PLoS ONE, 2009, 4(11):e7872.
    [41]
    Rohan JN, Weigel NL. 1Alpha, 25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells[J]. Endocrinology, 2009, 150(5):2046-2054.
    [42]
    Rawson JB, Sun Z, Dicks E, et al. Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients[J]. Nutr Cancer, 2012, 64(7):919-928.
    [43]
    Aguilera O, Pena C, Garcia JM, et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha, 25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells[J]. Carcinogenesis, 2007, 28(9):1877-1884.
    [44]
    Ben-Shoshan M, Amir S, Dang DT, et al. 1alpha, 25-dihydroxyvitamin D3(Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells[J]. Mol Cancer Ther, 2007, 6(4):1433-1439.
    [45]
    Chung I, Han G, Seshadri M, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo[J]. Cancer Res 2009, 69(3):967-975.
    [46]
    Morelli S, Buitrago C, Boland R, et al. The stimulation of MAP kinase by 1, 25(OH)(2)-vitamin D(3) in skeletal muscle cells is mediated by protein kinase C and calcium[J]. Mol Cell Endocrinol, 2001, 173(1-2):41-52.
    [47]
    Goeman F, De Nicola F, De Meo PD, et al. VDR primary targets by genome-wide transcriptional profiling[J]. J Steroid Biochem, 2014, 143:348-356.
    [48]
    Beaudin SG, Robilotto S, Welsh J. Comparative regulation of gene expression by 1, 25-dihydroxyvitamin D3 in cells derived from normal mammary tissue and breast cancer[J]. J Steroid Biochem, 2015, 148:96-102.
    [49]
    Zhang Z, Zhang H, Hu Z, et al. Synergy of 1, 25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells[J]. Oncol Lett, 2014, 8(3):1348-1354.
    [50]
    Linnewiel-Hermoni K, Khanin M, Danilenko M, et al. The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity[J]. Arch Biochem Biophys, 2015, 572:28-35.
    [51]
    Meeker S, Seamons A, Paik J, et al. Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer[J]. Cancer Res, 2014, 74(16):4398-4408.
    [52]
    Rebel H, der Spek CD, Salvatori D, et al. UV exposure inhibits intestinal tumor growth and progression to malignancy in intestine-specific Apc mutant mice kept on low vitamin D diet[J]. Int J Cancer, 2015, 136(2):271-277.
    [53]
    Kasiappan R, Sun Y, Lungchukiet P, et al. Vitamin D suppresses leptin stimulation of cancer growth through microRNA[J]. Cancer Res, 2014, 74(21):6194-6204.
    [54]
    Lang K, Ratke J. Leptin and adiponectin:new players in the field of tumor cell and leukocyte migration[J]. Cell Commun Signal, 2009, 7:27.
    [55]
    Skaaby T, Husemoen LL, Thyssen JP, et al. Filaggrin loss-offunction mutations and incident cancer:a population-based study[J]. Brit J Dermatol, 2014, 171(6):1407-1414.
    [56]
    Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases[J]. New Engl J Med, 2011, 365(14):1315-1327.
    [57]
    Thyssen JP, Thuesen B, Huth C, et al. Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxyvitamin D concentrations[J]. J Allergy Clin Immun, 2012, 130(5):1204-1207.e1202.
    [58]
    Moy KA, Mondul AM, Zhang H, et al. Genome-wide association study of circulating vitamin D-binding protein[J]. Am J Clin Nutr, 2014, 99(6):1424-1431.
    [59]
    Ashktorab H, Nguza B, Fatemi M, et al. Case-control study of vitamin D, dickkopf homolog 1(DKK1) gene methylation, VDR gene polymorphism and the risk of colon adenoma in African Americans[J]. PLoS ONE, 2011, 6(10):e25314.
    [60]
    Atoum MF, Tchoporyan MN. Association between circulating vitamin D, the Taq1 vitamin D receptor gene polymorphism and colorectal cancer risk among Jordanians[J]. Asian Pac J Cancer Prev, 2014, 15(17):7337-7341.
    [61]
    Kostner K, Denzer N, Muller CSL, et al. The relevance of Vitamin D receptor (VDR) gene polymorphisms for cancer:a review of the literature[J]. Anticancer Res, 2009, 29(9):3511-3536.
    [62]
    Serrano D, Gnagnarella P, Raimondi S, et al. Meta-analysis on vitamin D receptor and cancer risk:focus on the role of TaqI, ApaI, and Cdx2 polymorphisms[J]. Eur J Cancer Prev, 2015.
    [63]
    Gnagnarella P, Pasquali E, Serrano D, et al. Vitamin D receptor polymorphism FokI and cancer risk:a comprehensive meta-analysis[J]. Carcinogenesis, 2014, 35(9):1913-1919.
    [64]
    Raimondi S, Pasquali E, Gnagnarella P, et al. BsmI polymorphism of vitamin D receptor gene and cancer risk:A comprehensive meta-analysis[J]. Mut Res-Fund Mol M, 2014, 769:17-34.
    [65]
    Anderson LN, Cotterchio M, Knight JA, et al. Genetic variants in Vitamin D pathway genes and risk of pancreas cancer; results from a population-based case-control study in Ontario, Canada[J]. PLoS ONE, 2013, 8(6):e66768.
    [66]
    Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality:a meta-analysis[J]. Br J Cancer, 2014, 110(11):2772-2784.
    [67]
    Wang J, Eliassen AH, Spiegelman D, et al. Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses' Health Study II[J]. Cancer Cause Contr, 2014, 25(7):819-827.
    [68]
    Li M, Chen P, Li J, et al. Review:the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes:a systematic review and meta-analysis[J]. J Clin Endocr Met, 2014, 99(7):2327-2336.
    [69]
    Weinstein SJ, Purdue MP, Smith-Warner SA, et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the prostate, lung, colorectal and ovarian cancer screening trial[J]. Int J Cancer, 2015, 136(6):E654-E664.
    [70]
    Anic GM, Weinstein SJ, Mondul AM, et al. Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer[J]. PLoS One, 2014, 9(7):e102966.
    [71]
    Zgaga L, Theodoratou E, Farrington SM, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer[J]. J Clin Oncol, 2014, 32(23):2430-2439.
    [72]
    Kristal AR, Till C, Song X, et al. Plasma vitamin D and prostate cancer risk:results from the selenium and Vitamin E cancer prevention trial[J]. Cancer Epidem Biomar, 2014, 23(8):1494-1504.
    [73]
    Schenk JM, Till CA, Tangen CM, et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer:results from the prostate cancer prevention trial[J]. Cancer Epidem Biomar, 2014, 23(8):1484-1493.
    [74]
    Cheng TY, Goodman GE, Thornquist MD, et al. Estimated intake of vitamin D and its interaction with vitamin A on lung cancer risk among smokers[J]. Int J Cancer, 2014, 135(9):2135-2145.
    [75]
    Ng K, Scott JB, Drake BF, et al. Dose response to vitamin D supplementation in African Americans:results of a 4-arm, randomized, placebo-controlled trial[J]. Am J Clin Nutr, 2014, 99(3):587-598.
    [76]
    Chandler PD, Scott JB, Drake BF, et al. Impact of vitamin D supplementation on inflammatory markers in African Americans:results of a four-arm, randomized, placebocontrolled trial[J]. Cancer Prev Res 2014, 7(2):218-225.
    [77]
    Fabian C. Modulation of breast cacner risk biomarkers by high dose vitamin D[J]. ClinicalTrials.gov, 2010.
    [78]
    University of Illinois at Chicago. Efficacy of vitamin D in colorectal cancer chemoprevention[EB/OL]. 2012:ClinicalTrials.gov.
    [79]
    Murphy AB, Nyame Y, Martin IK, et al. Vitamin D deficiency predicts prostate biopsy outcomes[J]. Clin Cancer Res, 2014, 20(9):2289-2299.
    [80]
    Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer:a prospective nested case-control study[J]. J Natl Cancer I, 2012, 104(9):690-699.
    [81]
    Gambichler T, Bindsteiner M, Hoxtermann S, et al. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma[J]. Brit J Dermatol, 2013, 168(3):625-628.
    [82]
    Bade B, Zdebik A, Wagenpfeil S, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis[J]. PLoS ONE, 2014, 9(12):e112863.
    [83]
    Wesa KM, Segal NH, Cronin AM, et al. Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer:a retrospective analysis[J]. Nutr Cancer, 2015, 67(3):424-430.
    [84]
    Lee HJ, Muindi JR, Tan W, et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia[J]. Cancer, 2014, 120(4):521-529.
    [85]
    Peiris AN, Bailey BA, Manning T. Relationship of vitamin D monitoring and status to bladder cancer survival in veterans[J].South Med J, 2013, 106(2):126-130.
    [86]
    Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement[J]. Am J Clin Nutr, 2006, 84(4):694-697.
    [87]
    Leyssens C, Verlinden L, Verstuyf A. The future of vitamin D analogs[J]. Front Physiol, 2014, 5:122.
    [88]
    Mazzaferro S, Goldsmith D, Larsson TE, et al. Vitamin D metabolites and/or analogs:which D for which patient?[J]. Curr Vasc Pharmacol, 2014, 12(2):339-349.
    [89]
    Cheung FS, Lovicu FJ, Reichardt JK. Current progress in using vitamin D and its analogs for cancer prevention and treatment[J]. Expert Rev Anticanc, 2012, 12(6):811-837.
    [90]
    Brown AJ, Slatopolsky E. Vitamin D analogs:therapeutic applications and mechanisms for selectivity[J]. Mol Aspects Med, 2008, 29(6):433-452.
    [91]
    Sintov AC, Yarmolinsky L, Dahan A, et al. Pharmacological effects of vitamin D and its analogs:recent developments[J]. Drug Discov Today, 2014, 19(11):1769-1774.
    [92]
    Hylander E, Jarnum S. 1-Hydroxyvitamin D3 in Intestinal Calcium Malabsorption[J]. Scand J Gastroentero, 1980, 15(4):443-448.
    [93]
    Hellstrom E, Robert KH, Samuelsson J, et al. Treatment of myelodysplastic syndromes with retinoic acid and 1 alphahydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG)[J]. Eur J Haematol, 1990, 45(5):255-261.
    [94]
    Motomura S, Kanamori H, Maruta A, et al. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes[J]. Am J Hematol, 1991, 38(1):67-68.
    [95]
    Petrini M, Caracciolo F, Corini M, et al. Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia:pilot study[J]. Haematologica, 1991, 76(3):200-203.
    [96]
    Petrini M, Caracciolo F, Carulli G, et al. Vitamin D3 administration and multidrug resistance in acute nonlymphoblastic leukemia[J]. Acta Haematol-Basel, 1993, 89(4):184-188.
    [97]
    Trouillas P, Honnorat J, Bret P, et al. Redifferentiation therapy in brain tumors:long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol[J]. J Neuro-Oncol, 2001, 51(1):57-66.
    [98]
    Obara W, Mizutani Y, Oyama C, et al. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma[J]. Int J Urol, 2008, 15(9):794-799.
    [99]
    Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo[J]. Biochem Pharmacol, 1988, 37(5):889-895.
    [100]
    Bower M, Colston KW, Stein RC, et al. Topical calcipotriol treatment in advanced breast cancer[J]. Lancet, 1991, 337(8743):701-702.
    [101]
    O'Brien ME, Talbot D, Maclennan K, et al. Inefficacy of calcipotriol in skin metastases from breast cancer[J]. Lancet, 1993, 342(8877):994.
    [102]
    Liu G, Oettel K, Ripple G, et al. Phase I trial of 1-hydroxyvitamin D2 in patients with hormone refractory prostate cancer[J]. Clin Cancer Res, 2002, 8(9):2820-2827.
    [103]
    Liu G, Wilding G, Staab MJ, et al. Phase II study of 1-hydroxyvitamin D2 in the treatment of advanced androgen-independent prostate cancer[J]. Clin Cancer Res, 2003, 9(11):4077-4083.
    [104]
    Attia S, Eickhoff J, Wilding G, et al. Randomized, doubleblinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer[J]. Clin Cancer Res, 2008, 14(8):2437-2443.
    [105]
    Gee J, Bailey H, Kim K, et al. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin[J]. Prostate, 2013, 73(9):970-978.
    [106]
    Petrich A, Kahl B, Bailey H, et al. Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome[J]. Leukemia Lymphoma, 2008, 49(1):57-61.
    [107]
    M. D. Anderson Cancer Center. Doxercalciferol in recurrent pediatric solid tumors[EB/OL]. 2007:ClinicalTrials.gov.
    [108]
    Zhou JY, Norman AW, Lubbert M, et al. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization[J]. Blood, 1989, 74(1):82-93.
    [109]
    Wieder R, Novick SC, Hollis BW, et al. Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies[J]. Invest New Drug, 2003, 21(4):445-452.
    [110]
    Jain RK, Trump DL, Egorin MJ, et al. A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors[J]. Invest New Drug, 2011, 29(6):1420-1425.
    [111]
    Verlinden L, Verstuyf A, Van Camp M, et al. Two novel 14-Epi-analogues of 1, 25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo[J]. Cancer Res, 2000, 60(10):2673-2679.
    [112]
    Medioni J, Deplanque G, Ferrero JM, et al. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients[J]. Clin Cancer Res, 2014, 20(17):4471-4477.
    [113]
    Hybrigenics launches phase II clinical study of inecalcitol in chronic myeloid leukemia[C]. LSP, 2015.
    [114]
    Chen TC, Schwartz GG, Burnstein KL, et al. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha, 25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer[J]. Clin Cancer Res, 2000, 6(3):901-908.
    [115]
    Schwartz GG, Hall MC, Stindt D, et al. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2(paricalcitol) in advanced, androgen-insensitive prostate cancer[J]. Clin Cancer Res, 2005, 11(24 Pt 1):8680-8685.
    [116]
    Lawrence JA, Akman SA, Melin SA, et al. Oral paricalcitol (19-nor-1, 25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer:a feasibility trial[J]. Cancer Biol Ther, 2013, 14(6):476-480.
    [117]
    Colston KW, Mackay AG, James SY, et al. EB1089:a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro[J]. Biochem Pharmacol, 1992, 44(12):2273-2280.
    [118]
    Gulliford T, English J, Colston KW, et al. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer[J]. Brit J Cancer, 1998, 78(1):6-13.
    [119]
    Evans TR, Colston KW, Lofts FJ, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer[J]. Brit J Cancer, 2002, 86(5):680-685.
    [120]
    Dalhoff K, Dancey J, Astrup L, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma[J]. Brit J Cancer, 2003, 89(2):252-257.
    [121]
    LEO Pharma. Seocalcitol versus placebo in advanced hepatocellular carcinoma[J]. Clinical Trials. Gov, 2007.
    [122]
    LEO Pharma. Seocalcitol versus placebo in the adjuvant treatment of hepatocellular carcinoma[J]. Clinical Trials. Gov, 2007.
    [123]
    Brard L, Lange TS, Robison K, et al. Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines[J]. Gynecol Oncol, 2011, 123(2):370-378.
    [124]
    Chen B, Kawai M, Wu-Wong JR. Synthesis of VS-105:A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects[J]. Bioorg Med Chem Lett, 2013, 23(21):5949-5952.
    [125]
    Ma Y, Yu WD, Hidalgo AA, et al. Inecalcitol, an analog of 1, 25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system[J]. Cell Cycle, 2013, 12(5):743-752.
    [126]
    Chen J, Wang J, Kim TK, et al. Novel vitamin D analogs as potential therapeutics:metabolism, toxicity profiling, and antiproliferative activity[J]. Anticancer Res, 2014, 34(5):2153-2163.
    [127]
    Chiang KC, Yeh CN, Hsu JT, et al. The vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cells[J]. Cancer Lett, 2014, 354(2):235-244.
    [128]
    Deluca HF. The development of a bone- and parathyroidspecific analog of vitamin D:2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3[J]. Bonekey Rep, 2014, 3:514.
    [129]
    Kudo T, Ishizawa M, Maekawa K, et al. Combination of triple bond and adamantane ring on the vitamin D side chain produced partial agonists for vitamin D receptor[J]. J Med Chem, 2014, 57(10):4073-4087.
    [130]
    Slominski AT, Zmijewski MA, Semak I, et al. Cytochromes p450 and skin cancer:role of local endocrine pathways[J]. Anticancer Agents Med Chem, 2014, 14(1):77-96.
    [131]
    Fred Hutchison Cancer Research Center. Vitamin D, diet, and activity study (ViDA)[EB/OL]. 2010:ClinicalTrials.gov, NCT01240213.
    [132]
    Shanghai Jiao Tong University School of Medicine. Study of folic acid, calcium and Vitamin D in preventing colorectal polyps and colorectal cancer[EB/OL]. 2014:ClinicalTrials.gov, NCT0206688.
    [133]
    Brigham and Women's Hospital. Vitamin and Omega-3 Trial (VITAL)[EB/OL]. 2010:ClinicalTrials.gov, NCT01169259.
    [134]
    University of Eastern Finland. Finnish Vitamin D Trial (FIND)[EB/OL]. 2011:ClinicalTrials.gov, NCT01463813.
    [135]
    Emory University. Calcium/Vitamin D, biomarkers colon polyp prevention (PPS4B)[EB/OL]. 2006:ClinicalTrials.gov, NCT00399607.
    [136]
    Southwest Oncology Group. S0812 high dose cholecalciferol in premenopausal women at high-risk for breast cancer[EB/OL]. 2010:ClinicalTrials.gov, NCT01097278.
    [137]
    Johns Hopkins University. Study of high-dose oral Vitamin D for the prevention of liver cancer[EB/OL]. 2013:ClinicalTrials.gov, NCT01956864.
    [138]
    Creighton University. Clinical trial of Vitamin D3 to reduce cancer risk in postmenopausal women (CAPS)[EB/OL]. 2010:ClinicalTrials.gov, NCT01052051.
    • Related Articles

  • Cited by

    Periodical cited type(45)

    1. Tomer, R., Sharma, I., Sobti, R.C. Dietary supplements in cancer prevention and therapy. Handbook of Oncobiology: From Basic to Clinical Sciences, 2024.
    2. Al-Ali, L., Al-Ani, R.J., Saleh, M.M. et al. Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia. Saudi Pharmaceutical Journal, 2024, 32(2): 101931.
    3. Amaral, A.R., Finardi, G.L.F., Marchi, P.H. et al. Connection between nutrition and oncology in dogs and cats: perspectives, evidence, and implications—a comprehensive review. Frontiers in Veterinary Science, 2024, 11: 1490290.
    4. Sruthi, P., Priya, M., Varghese, T.P. et al. Role of Vitamin D in Gynecological Cancer: State of the Art. Current Cancer Therapy Reviews, 2024, 20(6): 569–577.
    5. Doshantapeh, A.G., Madani, M.H., Khodaparast, A. et al. Association between vitamin D and bladder neoplasm; a systematic review and meta-analysis. Journal of Nephropharmacology, 2024, 13(2): e11668.
    6. Delanghe, J.R., Speeckaert, M.M., Maenhout, T. Factors to take into account when interpreting 25-hydroxy-vitamin D serum levels. Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine, 2024, 79(2): 97–102.
    7. Hung, M., Almpani, K., Thao, B. et al. Vitamin D in the Prevention and Treatment of Oral Cancer: A Scoping Review. Nutrients, 2023, 15(10): 2346.
    8. Nigam, K., Singh, N., Yadav, S.K. et al. The Taq 1 polymorphism of Vitamin D receptor gene is associated with oral cancer and preoral cancer in North Indian population. Journal of Cancer Research and Therapeutics, 2023, 19(2): 403–407.
    9. Ehsanzade, S., Sheikhan, Z., Farzaneh, F. et al. Relationship between Vitamin D and Human Papillomavirus Infection: A Comparative Study. Iranian Journal of Obstetrics, Gynecology and Infertility, 2022, 25(9): 79–86.
    10. Gu, I., Gregory, E., Atwood, C. et al. Exploring the Role of Metabolites in Cancer and the Associated Nerve Crosstalk. Nutrients, 2022, 14(9): 1722.
    11. Varghese, J.E., Balasubramanian, B., Velayuthaprabhu, S. et al. Therapeutic effects of vitamin D and cancer: An overview. Food Frontiers, 2021, 2(4): 417–425.
    12. Mejía-Rodríguez, F., Flores-Aldana, M.E., Quezada-Sánchez, A.D. et al. Association between predictors of vitamin d serum levels and risk of retinoblastoma in children: A case-control study. Nutrients, 2021, 13(8): 2510.
    13. Li, Z., Wu, L., Zhang, J. et al. Effect of Vitamin D Supplementation on Risk of Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Nutrition, 2021, 8: 655727.
    14. Piotrowska, A., Wierzbicka, J., Kwiatkowska, K. et al. Antiproliferative activity of side-chain truncated vitamin D analogs (PRI-1203 and PRI-1204) against human malignant melanoma cell lines. European Journal of Pharmacology, 2020, 881: 173170.
    15. Attia, Y.M., Hammam, O.A., Ammar, R.A. et al. Crosstalk between aldehyde dehydrogenase-1 and chemoresistance in breast cancer: Insights into the role of vitamin D3. Life Sciences, 2020, 253: 117733.
    16. Shamsi, U., Usman, S. Causal association of Vitamin D deficiency with cancer: More research needed. Cancer Research, Statistics, and Treatment, 2020, Cancer Research: Statistics, and Treatment.
    17. Sartaj, A., Baboota, S., Ali, J. Nanomedicine: A promising avenue for the development of effective therapy for breast cancer. Current Cancer Drug Targets, 2020, 20(8): 603–615.
    18. Guo, J., Wang, B., Hou, W. et al. Risk factors for elevated serum colorectal cancer markers in patients with type 2 diabetes mellitus. Open Life Sciences, 2020, 15(1): 267–273.
    19. Zafalon, R.V.A., Risolia, L.W., Pedrinelli, V. et al. Vitamin D metabolism in dogs and cats and its relation to diseases not associated with bone metabolism. Journal of Animal Physiology and Animal Nutrition, 2020, 104(1): 322–342.
    20. Jawiarczyk-Przybyłowska, A., Halupczok-żyła, J., Kolačkov, K. et al. Association of vitamin d receptor polymorphisms with activity of acromegaly, vitamin D status and risk of osteoporotic fractures in acromegaly patients. Frontiers in Endocrinology, 2019, 10(SEP): 643.
    21. Bagatini, M.D., Bertolin, K., Bridi, A. et al. 1α, 25-Dihydroxyvitamin D3 alters ectonucleotidase expression and activity in human cutaneous melanoma cells. Journal of Cellular Biochemistry, 2019, 120(6): 9992–10000.
    22. Guo, J., Sun, C., Wang, B. et al. Associations between Vitamin D and β-cell function and colorectal cancer-associated tumor markers in Chinese type 2 diabetic patients with albuminuria. Clinical Laboratory, 2019, 65(4): 641–649.
    23. Fathi, N., Ahmadian, E., Shahi, S. et al. Role of vitamin D and vitamin D receptor (VDR) in oral cancer. Biomedicine and Pharmacotherapy, 2019, 109: 391–401.
    24. Maher, H.M., Alzoman, N.Z., Shehata, S.M. Ultra-performance LC-MS/MS study of the pharmacokinetic interaction of imatinib with selected vitamin preparations in rats. Bioanalysis, 2018, 10(14): 1099–1113.
    25. Zhang, T., Zhang, H., He, L. et al. Potential use of 1-25-dihydroxyvitamin d in the diagnosis and treatment of papillary thyroid cancer. Medical Science Monitor, 2018, 24: 1614–1623, 909544.
    26. Špániková, B., Špánik, S. The role of Vitamin D in the treatment of secondary osteoporosis in cancer patients | Miesto a postavenie vitamínu D v liečbe sekundárnej osteoporózy u onkologických pacientov. Clinical Osteology, 2018, 23(4): 169–175.
    27. Špániková, B.. Secondary osteoporosis in patients with malignancies | Sekundárna osteoporóza pri nádorových ochoreniach. Clinical Osteology, 2018, 23(1): 9–17.
    28. Santucci, K.L., Baust, J.M., Snyder, K.K. et al. Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model. Cancer Control, 2018, 25(1)
    29. Anisiewicz, A., Pawlik, A., Filip-Psurska, B. et al. Unfavorable effect of calcitriol and its low-calcemic analogs on metastasis of 4T1 mouse mammary gland cancer. International Journal of Oncology, 2018, 52(1): 103–126.
    30. Slominski, A.T., Kim, T.-K., Hobrath, J.V. et al. Endogenously produced nonclassical vitamin D hydroxy-metabolites act as “biased” agonists on VDR and inverse agonists on RORα and RORγ. Journal of Steroid Biochemistry and Molecular Biology, 2017, 173: 42–56.
    31. Farrag, S.E., Dwivedi, A.K., Otoukesh, S. et al. Prevalence of Low Vitamin D in Patients with Breast Cancer in a Predominantly Hispanic Population at the American-Mexican Border. Nutrition and Cancer, 2017, 69(6): 819–824.
    32. Lorenzo-Lorenzo, I., Fernández-Perez, I., Alonso-Herrero, A. et al. Breast cancer chemoprevention: What and when?. Cancer and Chemotherapy Reviews, 2017.
    33. Fatima, S., Rafique, A., Tehsin, F. Vitamin D deficiency in breast cancer patients and its association with histopathological tumor characteristics. Medical Forum Monthly, 2017, 28(3): 132–135.
    34. Grosso, G.. Milk and Chronic-Degenerative Diseases: Main Components and Potential Mechanisms. Dairy in Human Health and Disease across the Lifespan, 2017.
    35. Bolerazska, B., Rabajdova, M., Spakova, I. et al. Current knowledge on the active form of vitamin D synthesized in the skin and its effects on malignant melanoma. Neoplasma, 2017, 64(1): 1–12.
    36. Schwalb, M., Taubmann, M., Hines, S. et al. Clinical observation of a novel, complementary, immunotherapeutic approach based on ketogenic diet, chondroitin sulfate, vitamin D3, oleic acid and a fermented milk and colostrum product. American Journal of Immunology, 2016.
    37. Merker, M., Grädel, L., Mueller, B. et al. Vitamin D Deficiency in Medical Inpatients | Vitamin-D-Mangel bei hospitalisierten internistischen Patienten. Aktuelle Ernahrungsmedizin, 2016, 41(5): 370–378.
    38. Zhan, R., Shen, X., Ma, Z. et al. Dietary vitamin D intake and risk of non-small cell lung cancer: A matched case-control study. Translational Cancer Research, 2016, 5(4): 470–475.
    39. Shekarriz-Foumani, R., Khodaie, F. The correlation of plasma 25-hydroxyvitamin d deficiency with risk of breast neoplasms: A systematic review. International Journal of Cancer Management, 2016, 9(3): 1–7, e4469.
    40. Piotrowska, A., Wierzbicka, J., Ślebioda, T. et al. Vitamin D derivatives enhance cytotoxic effects of H2O2 or cisplatin on human keratinocytes. Steroids, 2016, 110: 49–61.
    41. Piotrowska, A., Wierzbicka, J., Nadkarni, S. et al. Antiproliferative activity of double point modified analogs of 1, 25-dihydroxyvitamin D2 against human malignant melanoma cell lines. International Journal of Molecular Sciences, 2016, 17(1): 76.
    42. Leung, H.W.C., Muo, C.-H., Liu, C.-F. et al. Vitamin D3 intake dose and common cancer: A population-based case control study in a Chinese population. Journal of Cancer, 2016, 7(14): 2028–2034.
    43. Özgö, E., Yilmaz, N., Başer, E. et al. Could 25-oh Vitamin D deficiency be a reason for hpv infection persistence in cervical premalignant lesions?. Journal of Experimental Therapeutics and Oncology, 2016.
    44. Grant, W.B.. The role of geographical ecological studies in identifying diseases linked to UVB exposure and/or vitamin D. Dermato-Endocrinology, 2016.
    45. Graedel, L., Merker, M., Felder, S. et al. Vitamin D deficiency strongly predicts adverse medical outcome across different medical inpatient populations results from a prospective study. Medicine (United States), 2016, 95(19): e3533.

    Other cited types(0)

Catalog

    Get Citation
    XML

    Article Metrics

    Article views (4448) PDF downloads (813) Cited by(45)
    Author Guidelines
    Related Links
    weidian_buy
    taobao_buy

    Copyright Reserved by China Pharmaceutical University..

    Address: No. 24, Tongjiaxiang Nanjing 210009 China    Call: 025-83271565 025-83271229    E-mail: cjnm@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd. Technical support: info@rhhz.net Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return